Huang et al. showed that CCL5 released by TAMs enhances metastasis by activating the STAT3-β-catenin pathway, whereas silencing CCL5 in TAMs reduces tumor growth and metastasis in prostate cancer [66]. The gene discussed is CCL5; the disease is neoplasm.